Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.55 |
| ▸ | LMNA | P02545 | 3/20 | 0.54 |
| ▸ | POLB | P06746 | 2/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2448445 | 1.00 | ALDH1A1 (0.55) | ALDH1A1LMNAPOLBNPC1KMT2A | |
| SCHEMBL2448446 | 1.00 | ALDH1A1 (0.55) | ALDH1A1LMNAPOLBNPC1KMT2A | |
| SCHEMBL25174357 | 0.85 | ALDH1A1 (0.52) | ALDH1A1LMNAPOLBNPC1KMT2A | |
| SCHEMBL27006651 | 0.84 | ALDH1A1 (0.70) | ALDH1A1LMNAPOLBNPC1KMT2A | |
| SCHEMBL2061869 | 0.84 | NPC1 (0.65) | ALDH1A1LMNAPOLBNPC1KMT2A | |
| SCHEMBL9976087 | 0.83 | ALDH1A1 (0.73) | ALDH1A1LMNAPOLBNPC1KMT2A | |
| SCHEMBL30610305 | 0.83 | ALDH1A1 (0.73) | ALDH1A1LMNAPOLBNPC1KMT2A | |
| Hydrochloric Acid SCHEMBL27620227 | 0.81 | ALDH1A1 (0.51) | ALDH1A1LMNAPOLBNPC1KMT2A | |
| SCHEMBL21124439 | 0.79 | ALDH1A1 (0.64) | ALDH1A1LMNAPOLBNPC1KMT2A | |
| SCHEMBL4626322 | 0.79 | ALDH1A1 (0.64) | ALDH1A1LMNAPOLBNPC1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1446401-B1 | C5-modified indazolylpyrrolotriazines | BRISTOL MYERS SQUIBB CO (US) | 2011-09-14 | — | — | EP | disclosed |
| WO-2010049731-A1 | PYRAZOLO- AND IMIDAZOPYRIDINYLPYRIMIDINEAMINES AS IGF-1R TYROSINE KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2010-05-06 | — | — | WO | disclosed |
| US-20100105655-A1 | NOVEL COMPOUNDS 515 | ASTRAZENECA AB | 2010-04-29 | — | — | US | disclosed |
| EP-1446401-A4 | C-5 MODIFIED INDAZOLYLPYRROLOTRIAZINES | BRISTOL MYERS SQUIBB CO (US) | 2006-04-12 | — | — | EP | disclosed |
| US-20050209235-A1 | C-5 Modified indazolylpyrrolotriazines | MASTALERZ HAROLD | 2005-09-22 | — | — | US | disclosed |
| US-6908916-B2 | C-5 modified indazolylpyrrolotriazines | BRISTOL MYERS SQUIBB COMPANY (US) | 2005-06-21 | — | — | US | disclosed |
| EP-1446401-A2 | C-5 MODIFIED INDAZOLYLPYRROLOTRIAZINES | Bristol-Myers Squibb Company (US) | 2004-08-18 | — | — | EP | disclosed |
| US-20030186983-A1 | C-5 Modified indazolylpyrrolotriazines | BRISTOL-MYERS SQUIBB COMPANY | 2003-10-02 | — | — | US | disclosed |
| WO-2003042172-A2 | C-5 MODIFIED INDAZOLYLPYRROLOTRIAZINES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030186983-A1 | C-5 Modified indazolylpyrrolotriazines | ERBB2, ERBB4, EGFR | ALDH1A1 2091/4885LMNA 4225/4885POLB 4605/4885 |
| US-20050209235-A1 | C-5 Modified indazolylpyrrolotriazines | ERBB2, ERBB4, EGFR | ALDH1A1 2381/4885LMNA 4309/4885POLB 4643/4885 |
| US-20100105655-A1 | NOVEL COMPOUNDS 515 | TYMS, ABCG2, UMPS | ALDH1A1 649/4885LMNA 3341/4885POLB 233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.